Circulating sphingolipids, fasting glucose, and impaired fasting glucose: The Strong Heart Family Study.Citation: EBioMedicine. 41:44-49, 2019 Mar.PMID: 30594552Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Blood Glucose/an [Analysis] | *Cardiovascular Diseases/bl [Blood] | *Ceramides/bl [Blood] | Adult | Biomarkers/bl [Blood] | Cardiovascular Diseases/ep [Epidemiology] | Fasting/bl [Blood] | Female | Humans | Male | Middle AgedYear: 2019ISSN:
|Item type||Current library||Collection||Call number||Status||Date due||Barcode|
|Journal Article||MedStar Authors Catalog||Article||30594552||Available||30594552|
BACKGROUND: Animal studies suggest sphingolipids as an early marker of impaired glucose metabolism; however, research in humans is limited. We evaluated whether individual sphingolipid species were associated with fasting plasma glucose and incident impaired fasting glucose in a longitudinal cohort study.
Copyright (c) 2018 The Authors. Published by Elsevier B.V. All rights reserved.
FINDINGS: The average age of study participants was 38years; 41% were men. Ceramide, sphingomyelin, and glucosylceramide species levels were higher in older participants; lactosyl-ceramide levels were higher in participants with lower BMIs. In adjusted analyses, greater concentrations of most ceramide species and lower lactosyl- ceramide with palmitic acid (LC-16) were associated with higher glucose levels at baseline. We did not observe associations of sphingomyelin species or glucosyl-ceramide species with glucose levels. Associations of sphingolipid levels with fasting glucose levels at follow-up were similar but had greater uncertainty than associations with baseline glucose. Although no statistically significant associations of sphingolipids with incident impaired fasting glucose were present, results were similar to glucose analyses.
INTERPRETATION: We identified several ceramide species associated with higher fasting glucose levels and one sphingolipid, LC-16, that was associated with lower fasting glucose levels. These findings compliment previous research, which linked these sphingolipids with fasting insulin levels, and suggest that higher levels of these ceramides and lower LC-16 may be an early marker of impaired glucose metabolism. FUND: US National Institutes Health.
METHODS: We measured 15 sphingolipid species from blood samples collected in 2001-2003 from 2145 participants without prevalent diabetes in the Strong Heart Family Study. Fasting plasma glucose was measured in blood samples collected at baseline and follow-up (mean 5.5years after baseline).